CNBX Pharmaceuticals Inc. (CNBX)

OTCMKTS: CNBX · Delayed Price · USD
0.0300
+0.0050 (20.00%)
Mar 31, 2023, 12:29 PM EDT - Market open
Market Cap 1.20M
Revenue (ttm) n/a
Net Income (ttm) -2.76M
Shares Out 1.26M
EPS (ttm) -1.23
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 386,655
Open 0.0285
Previous Close 0.0250
Day's Range 0.0230 - 0.0300
52-Week Range 0.0200 - 12.0000
Beta 1.56
Analysts n/a
Price Target n/a
Earnings Date n/a

About CNBX

CNBX Pharmaceuticals Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of cannabinoid-based treatments and therapies for cancer. Its lead product candidate is RCC-33, an oral capsule containing a formulation of cannabinoids for the treatment of colorectal cancer. The company is also developing various drug candidates, including PLP-33 for the treatment of lateral spreading or sessile, and colorectal polyps during colonoscopy; BRST-33 to treat breast cancer; MLN-33 for the treatment of Melanoma; and ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2004
Employees 5
Stock Exchange OTCMKTS
Ticker Symbol CNBX
Full Company Profile

Financial Performance

Financial Statements

News

CNBX to Enter the Cancer Immunotherapy Market After Acquiring a Controlling Interest in TaGeza Biopharma

REHOVOT, Israel and BETHESDA, MD, Nov. 8, 2022 /PRNewswire/ -- CNBX Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related medicine, announced today that it has acqui...

5 months ago - PRNewsWire

CNBX Files New PCT Patent Application For Cannabinoids-Based Neoadjuvant Cancer Therapy

REHOVOT, Israel and BETHESDA, MD., Oct. 18, 2022 /PRNewswire/ -- CNBX Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced tod...

5 months ago - PRNewsWire

CNBX Patent Application "Composition and Method for Treating Cancer with Cannabinoids" Enters National Phase in US and Israel

REHOVOT, Israel and BETHESDA, Md. , Oct. 13, 2022 /PRNewswire/ - CNBX Pharmaceuticals Inc. (OTC-QB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced to...

6 months ago - PRNewsWire

CNBX Peer-reviewed Study: "Possible Future Therapeutic Value" for CNBX Proprietary Drug Candidate

REHOVOT, Israel and BETHESDA, Md. , Sept. 29, 2022 /PRNewswire/ -- CNBX Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced t...

6 months ago - PRNewsWire

CNBX Pharmaceuticals Announces New Patent Granted in Australia

REHOVOT, Israel and BETHESDA, MD., Sept. 28, 2022 /PRNewswire/ -- CNBX Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced to...

6 months ago - PRNewsWire

CNBX Pharmaceuticals Granted Patent in Hong Kong

TEL AVIV, Israel and BETHESDA, Md. , May 5, 2022  /PRNewswire/ -- CNBX Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, today announ...

11 months ago - PRNewsWire

Cannabics Pharmaceuticals Changes Name to CNBX Pharmaceuticals

TEL AVIV, Israel and BETHESDA, Md. , March 28, 2022 /PRNewswire/ --  Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, anno...

1 year ago - PRNewsWire

CNBX Selects API Supplier Purisys to Support Planned IND Fillings and Phase I/II (a) Clinical Trials

TEL AVIV, Israel and BETHESDA, Md., Nov. 4, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announce...

1 year ago - PRNewsWire

Meet CNBX at Radiation Therapy Conference (RTC) 2021 in Chicago

TEL AVIV, Israel and BETHESDA, Md., Oct. 26, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTC: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced...

1 year ago - PRNewsWire

Radiation Oncology Expert Joins Cannabics Pharmaceuticals' Board of Advisors

TEL AVIV, Israel and BETHESDA, Md., Oct. 25, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTC: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced...

1 year ago - PRNewsWire

EDISON Publishes Healthcare QuickView on Cannabics Pharmaceuticals: CNBX

TEL AVIV, Israel and BETHESDA, Md., Oct. 21, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTC: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced...

1 year ago - PRNewsWire

CNBX Director, Dr. Inbar Maymon-Pomeranchik, to Participate at MJBizCon in Las Vegas

TEL AVIV, Israel and BETHESDA, Md., Oct. 20, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTC: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced...

1 year ago - PRNewsWire

CEO of Cannabics Pharmaceuticals, Eyal Barad, to present at Edison Open Forum: Cannabinoids 2021

TEL AVIV, Israel and BETHESDA, Md., Oct. 19, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTC: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced...

1 year ago - PRNewsWire

Cannabics Pharmaceuticals Announces Two New Provisional Patents: Compositions and Methods For Treating Cancer

Cannabics Pharmaceuticals Inc. (OTC:CNBX), a global leader in the development of cancer-related cannabinoid-based medicine, announced on Monday that it has filed two new provisional patent application...

1 year ago - Benzinga

Cannabics Pharmaceuticals Files 2 Provisional Patents On Compositions and Methods for Treating Cancer

TEL AVIV, Israel and BETHESDA, Md., Oct. 18, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTC: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced...

1 year ago - PRNewsWire

Cannabics Announces New Corporate Logo, New Website and New Company Presentation

TEL AVIV, Israel and BETHESDA, Md., Sept. 30, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine and a p...

1 year ago - PRNewsWire

Gabriel Yariv, Executive Director of Cannabics Pharmaceuticals and Dr. David Sans will participate at the ICDP Summit in Boston

TEL AVIV, Israel and BETHESDA, Md., Sept. 22, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announ...

1 year ago - PRNewsWire

Cannabics Pharmaceuticals hires Healthcare Investment Banker Dr. David Sans in New York to expand CNBX in Mental Health Diseases

TEL AVIV, Israel and BETHESDA, Maryland, Sept. 21, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announce...

1 year ago - PRNewsWire

Neuropsychiatry Expert Dr. Ilya Reznik (MD) Joins Cannabics as Head of Psychedelic Inspired Medicine

TEL AVIV, Israel and BETHESDA, Md., Sept. 13, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine and a p...

1 year ago - PRNewsWire

Hemato-Oncology Expert, Dr. Sigal Tavor (MD) Joins Cannabics Pharmaceuticals' Board of Advisors

TEL AVIV, Israel and BETHESDA, Md., Aug. 23, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announc...

1 year ago - PRNewsWire

World-Renowned Melanoma Expert Joins Cannabics Pharmaceuticals' Board of Advisors

TEL AVIV, Israel and BETHESDA, Maryland, Aug. 4, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, ann...

1 year ago - PRNewsWire

Cannabics Pharmaceuticals Appoints a Second Independent Board Member

TEL AVIV, Israel and BETHESDA, Maryland, July 20, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, an...

1 year ago - PRNewsWire

Cannabics Pharmaceuticals Announces Appointment of New Independent Board Member

TEL AVIV, Israel and BETHESDA, Md., July 7, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announce...

1 year ago - PRNewsWire

Cannabics Pharmaceuticals' Drug Candidate Exhibits 30% Tumor Volume Reduction in Mice

TEL AVIV, Israel and BETHESDA, Md., June 28, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, release...

1 year ago - PRNewsWire

Cannabics Pharmaceuticals to launch Drug Development Programs for Prostate Cancer and Neurodegenerative & Mental Health Diseases

TEL AVIV, Israel and BETHESDA, Maryland, June 17, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, an...

1 year ago - PRNewsWire